Press release
Prostate Cancer Diagnostics Market is expected to grow with a double-digit staggering CAGR of 14.50% during 2022-2028
Expert Insights: Ask Analyst or Download Full Report with TOC & Figures: https://www.renub.com/prostate-cancer-diagnostics-market-p.php
Renub Research has lately published a report named "Prostate Cancer Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2022-2028," providing an exhaustive industry analysis that comprises of market share acumen. Furthermore, the report covers research of competitors and countries and the current surge in the Prostate Cancer Diagnostics Market.
Prostate Cancer Diagnostics Market will expand at a CAGR of 14.50% during 2022 to 2028. According to World Health Organisation (WHO), the prevalence of prostate cancer in 2023 is expected to be 14.1 million men, or 1.4% of the male population. The growing incidence of prostate cancer may be attributed to numerous elements, such as the growing old male residents, as they are at greater danger of encountering the disease. Increased recognition of prostate cancers has led to men seeking screenings, contributing to the growing number of patients diagnosed. Also, the availability of advanced diagnostic tests for prostate cancers has advanced detection abilities, resulting into various types of diagnoses being made.
Moreover, the surge in the prostate cancer diagnostics market is propelled by growing awareness campaigns that train the general public about the significance of early detection, leading to higher volume of screening and diagnosis amongst at-risk populations. Heightened focus empowers people to seek well timed scientific reviews and fosters proactive healthcare seeking behaviours, ensuring improved patient outcomes. As the stigma round prostate cancer diminishes and knowledge about available diagnostic alternatives spreads, more individuals are motivated to go through screenings, hence propelling the market's rise by addressing the ailment at its earliest and most treatable stage.
Innovations such as multiparametric MRI and molecular biomarker tests provide stronger detection and characterization of prostate cancer, allowing specific prognosis and customized treatment planning. These technologies enhance the general diagnostic accuracy, lessen needless biopsies, and help in figuring out aggressive tumours earlier. As healthcare systems integrate these modern tools, patients benefit from improved results, making superior diagnostic technology a key driver within the prostate cancer diagnostics market.
The Preliminary Test segment dominates the prostate cancer diagnostics market by identifying potential cases through tests like PSA and digital rectal exams.
As healthcare emphasizes early detection, the preliminary tests play a vital role in spotting threat, driving need for complete diagnostics. Their extensive use as leading screening equipment positions the Preliminary Test section to preserve the biggest market proportion, shaping powerful diagnostic pathways for prostate cancers.
The Prostate Cancer Antigen 3 (PCA3) Test is experiencing significant growth within the prostate cancer diagnostics market.
The PCA3 Test's targeted approach to prostate cancer gene expression complements disease evaluation accuracy. This non-invasive urine-based test reduces needless biopsies, identifying competitive tumours quicker for progressed patient handling. Aligned with personalised remedy and early intervention trends, its capacity to enhance diagnostic precision and optimize treatment selections drives vast increase in the evolving prostate cancer diagnostics market.
๐ญ๐๐ ๐ด๐๐๐ ๐ซ๐๐๐๐๐๐, ๐ฎ๐๐๐ ๐๐๐ Free Sample Report:https://www.renub.com/request-sample-page.php?gturl=prostate-cancer-diagnostics-market-p.php
Diagnostics centers hold dominance in the prostate cancer diagnostics market due to their specialized expertise and comprehensive range of diagnostic services.
Diagnostics centers provide advanced imaging, biomarker checks, and minimally invasive methods, making sure accurate prostate cancer detection and staging. Patients benefit complete assessments, well timed results, and customized treatment directions in a single place. With contemporary system and experienced experts, diagnostics facilities are pivotal in shaping the evolving landscape of prostate cancer diagnostics.
The Asia-Pacific region leads in the prostate cancer diagnostics market.
Rapid economic improvement has improved access to superior clinical technology, facilitating early detection and diagnosis. Moreover, the region's excessive incidence of prostate cancer, coupled with the adoption of revolutionary diagnostic techniques, drives market growth. As healthcare infrastructure expands and attention campaigns intensify, Asia-Pacific takes a leading-edge position in addressing prostate cancer, making it a leader in advancing diagnostics and patient outcomes within this market.
Competitive Landscape.
Abbott Laboratories, AstraZeneca, Bayer AG, F. Hoffman-La Roche AG, Hologic, Inc., Myriad Genetics, Inc., OPKO Health, Inc., Sanofi-Aventis, Siemens Healthineers AG, and Thermo Fisher Scientific. among other domestic competitors, are key participants in the prostate cancer diagnostics market.
Market Summary.
โข Diagnosis type- The report analyses the Prostate Cancer Diagnostics Market by diagnosis type from two different angles (preliminary test and confirmatory test).
โข Test type- According to test type, the Prostate Cancer Diagnostics Market is divided into three perspectives (PCA3, Trans-rectal Ultrasound, Biopsy).
โข End-User- A Renub Research report on the Prostate Cancer Diagnostics Market looks at end-users from four angles (Hospitals & Clinics, Diagnostics Centers, Research Institute, Others).
โข Region- There are five different perspectives on the Prostate Cancer Diagnostics Market by region (Northern Europe, Western Europe, South Europe, Eastern Europe, Micronesia, Melanesia, North America, South America, Central America, Middle Africa, Western Africa, Eastern Africa, North Africa, South Africa, South central Asia, Southeast Asia, Eastern Asia, Western Asia, Australia, and Caribbean).
โข Key Players- Every significant player in the Prostate Cancer Diagnostics Market has been discussed from three perspectives (Overview, Recent Developments, and Revenue) are Myriad Genetics, Inc., Abbott Laboratories, F. Hoffman-La Roche AG, Siemens Healthiness AG, OPKO Health, Inc., AstraZeneca, Bayer AG, Sanofi-Aventis, Thermo Fisher Scientific, and Hologic, Inc.
Related Reports
Europe Breast Cancer Screening Market: https://www.renub.com/europe-breast-cancer-screening-market-mammography-mri-and-ultrasound-forecast-to-2022-1097-p.php
Non-Invasive Prenatal Testing Market: https://www.renub.com/non-invasive-prenatal-testing-market-p.php
Breast Cancer Screening Market: https://www.renub.com/breast-cancer-screening-mammography-mri-and-ultrasound-market-and-forecast-worldwide-63-p.php
Multiple Myeloma Market: https://www.renub.com/multiple-myeloma-market-p.php
Wound Care Market: https://www.renub.com/wound-care-market-p.php
About the Company:
Renub Research is a Market Research and Information Analysis company with more than 14 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 7000 syndicated reports and worked on more than 500 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.
Media Contact:
Company Name: Renub Research
Contact Person: Rajat Gupta, Marketing Manager
Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)
Address: 225 Kristie Ln, Roswell, GA 30076
Email: info@renub.com
LinkedIn: https://in.linkedin.com/company/renub-research
Web: www.renub.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Prostate Cancer Diagnostics Market is expected to grow with a double-digit staggering CAGR of 14.50% during 2022-2028 here
News-ID: 3187166 • Views: โฆ
More Releases from Renub Resaecrh
Global Sports Medicine Market to Hit $12.32 Billion by 2033, Driven by Rising At โฆ
Sports Medicine Market Overview
The growing awareness of injury prevention, increased involvement in sports and physical activities, and advancements in medical technology are all contributing to the notable rise of the global sports medicine industry. The prevention, diagnosis, treatment, and rehabilitation of sports-related injuries are the primary goals of this specialized discipline, which serves athletes, fitness enthusiasts, and individuals who lead active lifestyles. The adoption of less invasive surgical procedures, theโฆ
U.S. Cosmetics Industry Set to Surge Past $149 Billion by 2033 Amid Rising Deman โฆ
United States Cosmetics Market Overview
According to Renub Research, with an absolute compound annual growth rate (CAGR) of 4.82% from 2025 to 2033, the United States cosmetics industry is expected to reach around US$ 149.53 billion in 2033, up from US$ 97.89 billion in 2024.
Growing consumer awareness of personal grooming and beauty improvement, particularly among millennial and Gen Z, is the primary factor driving the US industry. For example, according toโฆ
Global Non-Invasive Prenatal Testing Market to Triple by 2033, Surging to US$ 11 โฆ
Non-Invasive Prenatal Testing Market Overview
A type of prenatal screening called non-invasive prenatal testing (NIPT) uses a pregnant woman's blood sample to check for fetal abnormalities. By examining DNA fragments in the mother's blood, the test is primarily used to identify genetic abnormalities, such as Turner syndrome, Patau syndrome, Edwards syndrome, and Down syndrome. The treatment, which may be carried out after nine weeks of pregnancy, removes the needโฆ
Renub Research: Global Tractor Market Set to Plough Ahead, Reaching $111.22 Bill โฆ
Agricultural Tractors Market Overview
The growing need for automated solutions in contemporary farming is driving the rapid evolution of the agricultural tractor market. Precision agriculture, less manual work, and increased output are all made possible by tractors. To maximize field operations, farmers are implementing tractors equipped with cutting-edge technology, such as automation, telematics, and GPS, as the global demand for food increases. Trends such as climate change adaptation and sustainableโฆ
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by โฆ
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emergingโฆ
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio โฆ
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boostโฆ
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne โฆ
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of theโฆ
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve โฆ
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:โฆ
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance โฆ
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launchโฆ
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung โฆ
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. Forโฆ
